Top Markets
Coin of the day
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
株式のランク #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
株価
$1.73
最終同期: 2025-06-17
時価総額
$2.55M
変化(1日)
-0.29%
変化(1年)
0.00%
US
取引 Eiger BioPharmaceuticals, Inc. (EIGR)

カテゴリー

Eiger BioPharmaceuticals, Inc.(EIGR)のEPS
2026 時点のEPS TTM: 0
Eiger BioPharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Eiger BioPharmaceuticals, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS